One of the most formidable challenges in oncology is treatment resistance, a phenomenon that leads to poor prognosis by rendering standard therapies ineffective. Understanding why some cancers become resistant is critical for developing new strategies. Scientists have identified several mechanisms, including genetic mutations, tumor heterogeneity, and microenvironmental factors, that enable cancer cells to evade treatment.
Acquired resistance occurs when initially responsive tumors stop responding to therapy. This can result from drug efflux, activation of alternative signaling pathways, or enhanced DNA repair. For example, in non-small cell lung cancer, resistance to EGFR inhibitors often arises from secondary mutations like T790M. Similarly, in melanoma, BRAF inhibitor resistance can develop through MAPK pathway reactivation.
Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are pioneering approaches to overcome resistance. Calidi is developing oncolytic virus therapies that selectively infect and destroy cancer cells while stimulating an immune response. These therapies aim to target resistant tumor cells and enhance the efficacy of existing treatments.
Another avenue of research involves targeting the tumor microenvironment, which can shield cancer cells from drugs. Immune checkpoint inhibitors, for instance, have shown promise in reversing resistance by reactivating T cells. Combination therapies that simultaneously attack multiple pathways are also being explored to prevent resistance from emerging.
The implications of this research are profound. If scientists can unravel the mechanisms of resistance, they can design smarter treatments that adapt to cancer's evolution. This could significantly improve survival rates for patients with resistant cancers, such as pancreatic or triple-negative breast cancer.
For more information on the latest developments in biotech and life sciences, visit BioMedWire, a platform that delivers breaking news and insights to investors and the public.
